文献速递造血干细胞移植与细胞治疗白血病

一种生成T细胞受体缺陷型嵌合抗原受体T细胞的新方法

A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.
PubMed 文献 · Blood Adv · 2018-01-01

研究将抗CD3ε单链可变片段与21种胞内滞留氨基酸序列融合构建蛋白表达阻断剂(PEBL),在T细胞中转导后阻断表面CD3与TCRαβ表达;25次实验中TCRαβ中位表达从95.7%降至25.0%,CD3/TCRαβ细胞清除后得到几乎纯的TCRαβ阴性T细胞;抗CD3ε PEBL-T细胞表达抗CD19-41BB-CD3ζ CAR后仍具细胞因子分泌、长期增殖和杀伤CD19+白血病细胞能力,在免疫缺陷小鼠中GVHD潜能明显降低且可杀伤植入的白血病细胞。

要点

  • 抗CD3ε PEBL与CD3ε胞内共定位,阻断表面CD3和TCRαβ表达。
  • 25次实验中T淋巴细胞TCRαβ中位表达从95.7%降至25.0%。
  • PEBL与CAR可在单步流程中联合表达,易于适配现有细胞制备方案。

核心结论

  • PEBL阻断表面CD3/TCRαβ表达是制备同种异体CAR-T细胞的有效工具。
  • PEBL与CAR表达可在单步流程中实现,易于适配现有细胞制备方案,并可用于靶向其他T细胞分子以进一步增强CAR-T细胞疗法。

研究设计与样本

  • 将抗CD3ε单链可变片段与21种预测可使其滞留胞内的氨基酸序列组合构建PEBL,转导T细胞后检测表面CD3和TCRαβ表达。
  • 在25次实验中评估T淋巴细胞TCRαβ表达变化,并检测CD3/TCRαβ细胞清除效果。
  • 评估抗CD3ε PEBL-T细胞的信号、免疫表型、增殖及抗CD19-41BB-CD3ζ CAR后的功能。
  • 在免疫缺陷小鼠中评估抗CD3ε PEBL-T细胞的GVHD潜能及CAR转导后对植入白血病细胞的杀伤。

主要发现

  • 转导后多种PEBL与CD3ε胞内共定位,阻断表面CD3和TCRαβ表达。
  • 25次实验中T淋巴细胞TCRαβ中位表达从95.7%降至25.0%。
  • CD3/TCRαβ细胞清除后得到几乎纯的TCRαβ阴性T细胞。
  • 抗CD3ε PEBL消除TCRαβ介导的信号,不影响免疫表型或增殖。
  • 抗CD3ε PEBL-T细胞表达抗CD19-41BB-CD3ζ CAR后诱导细胞因子分泌、长期增殖和杀伤CD19+白血病细胞,速率达到或超过CD3/TCRαβ表达正常的CAR-T细胞。

临床怎么用

  • 作者认为PEBL阻断表面CD3/TCRαβ表达是制备同种异体CAR-T细胞的有效工具。
  • 作者指出PEBL与CAR表达可在单步流程中实现,易于适配现有细胞制备方案,并可用于靶向其他T细胞分子以进一步增强CAR-T细胞疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Practical methods are needed to increase the applicability and efficacy of chimeric antigen receptor (CAR) T-cell therapies. Using donor-derived CAR-T cells is attractive, but expression of endogenous T-cell receptors (TCRs) carries the risk for graft-versus-host-disease (GVHD). To remove surface TCRαβ, we combined an antibody-derived single-chain variable fragment specific for CD3ε with 21 different amino acid sequences predicted to retain it intracellularly. After transduction in T cells, several of these protein expression blockers (PEBLs) colocalized intracellularly with CD3ε, blocking surface CD3 and TCRαβ expression. In 25 experiments, median TCRαβ expression in T lymphocytes was reduced from 95.7% to 25.0%; CD3/TCRαβ cell depletion yielded virtually pure TCRαβ-negative T cells. Anti-CD3ε PEBLs abrogated TCRαβ-mediated signaling, without affecting immunophenotype or proliferation. In anti-CD3ε PEBL-T cells, expression of an anti-CD19-41BB-CD3ζ CAR induced cytokine secretion, long-term proliferation, and CD19+ leukemia cell killing, at rates meeting or exceeding those of CAR-T cells with normal CD3/TCRαβ expression. In immunodeficient mice, anti-CD3ε PEBL-T cells had markedly reduced GVHD potential; when transduced with anti-CD19 CAR, these T cells killed engrafted leukemic cells. PEBL blockade of surface CD3/TCRαβ expression is an effective tool to prepare allogeneic CAR-T cells. Combined PEBL and CAR expression can be achieved in a single-step procedure, is easily adaptable to current cell manufacturing protocols, and can be used to target other T-cell molecules to further enhance CAR-T-cell therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kamiya T, Wong D, Png YT, et al. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018. PMID: 29507075. doi:10.1182/bloodadvances.2017012823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。